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Abstract
In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T
cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor
prognosis. Besides the different clinical presentations of these lymphoma entities, there are variants of NLPHL with
considerable histopathologic overlap compared to THRLBCL. Especially THRLBCL-like NLPHL, a diffuse form of NLPHL, often
presents a histopathologic pattern similar to THRLBCL, suggesting a close relationship between both lymphoma entities. To
corroborate this hypothesis, we performed gene expression profiling of microdissected tumor cells of NLPHL, THRLBCL-like
NLPHL and THRLBCL. In unsupervised analyses, the lymphomas did not cluster according to their entity. Moreover, even in
supervised analyses, very few consistently differentially expressed transcripts were found, and for these genes the extent of
differential expression was only moderate. Hence, there are no clear and consistent differences in the gene expression of
the tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. Based on the gene expression studies, we identified BAT3/
BAG6, HIGD1A, and FAT10/UBD as immunohistochemical markers expressed in the tumor cells of all three lymphomas.
Characterization of the tumor microenvironment for infiltrating T cells and histiocytes revealed significant differences in the
cellular composition between typical NLPHL and THRLBCL cases. However, THRLBCL-like NLPHL presented a histopathologic
pattern more related to THRLBCL than NLPHL. In conclusion, NLPHL and THRLBCL may represent a spectrum of the same
disease. The different clinical behavior of these lymphomas may be strongly influenced by differences in the lymphoma
microenvironment, possibly related to the immune status of the patient at the timepoint of diagnosis.
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Introduction
Nodular lymphocyte predominant Hodgkin lymphoma
(NLPHL) is a germinal center (GC) B cell derived neoplasm
preferentially affecting young to middle aged male patients [1,2].
Diagnosis of NLPHL often reveals a limited stage disease with an
indolent clinical behavior [3]. In most cases the histopathologic
picture of NLPHL is dominated by a nodular infiltrate composed
of small reactive B cells and only few tumor cells, the lymphocyte
predominant (LP) cells [4]. However, cases of NLPHL have been
described showing a diffuse infiltrate of LP cells in a T cell and
histiocyte-rich background [5,6]. Six NLPHL variant patterns
have been defined by Fan et al., of which the patterns C and E
most closely resemble T cell/histiocyte rich large B cell lymphoma
(THRLBCL) (Fig. 1) [5]. Patients with NLPHL pattern E (in the
following called THRLBCL-like NLPHL) develop relapses more
frequently than patients with a typical nodular infiltrate [5]. 60%
of these rare THRLBCL-like NLPHL cases present with advanced
clinical stages (III/IV) [6].
THRLBCL is an aggressive B cell lymphoma and has been
recognized as a new entity in the WHO classification of tumors of
hematopoietic and lymphoid tissue [4]. It usually presents in
advanced clinical stages and patients affected are usually middle
aged males [7]. Some studies reported a poor clinical outcome
[7,8], whereas others found overall survival comparable to
conventional diffuse large B cell lymphoma (DLBCL) [9].
Nonetheless, prognosis of THRLBCL is worse than for NLPHL
[10]. The histopathologic picture of THRLBCL is dominated by a
diffuse T cell and histiocyte-rich infiltrate comprising only few
tumor cells [11]. Interestingly, there is a considerable diagnostic
overlap between THRLBCL and THRLBCL-like NLPHL. The
WHO classification [4] proposes to label cases with at least one
typical NLPHL nodule as THRLBCL-like NLPHL and to
distinguish these cases from primary THRLBCL.
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e78812The present study was aimed to clarify whether NLPHL and
THRLBCL as well as THRLBCL-like cases can be clearly
differentiated by global gene expression profiling (GEP) of the
tumor cells or the composition of the reactive background.
Materials and Methods
Patient Selection
Cases of all patients analyzed by GEP were selected and
reviewed by a hematopathologist panel (R.G., M.L.H., S.H.,
T.T.). THRLBCL-like NLPHL cases mostly resembled the
morphology of THRLBCL, but at least one typical nodule of
NLPHL was found. In the THRLBCL cases no coexisting
NLPHL was found. Of the typical NLPHL cases, 8 of 10 were
histologically classified as pattern A or B, and two cases were
classified as pattern F, according to Fan et al. [5]. Cases were
collected at the Dr. Senckenberg Institute of Pathology Frankfurt
am Main, Germany, the Department of Pathology University
Hospitals K.U.Leuven, Belgium, the Unit of lymphoid malignan-
cies Scientific Institute San Raffaele, Milan, Italy, the Department
of Pathology University of Brescia, Italy and the Department of
Pathology and Laboratory Medicine and the Centre for Lymphoid
Cancer British Columbia Cancer Agency, Vancouver, Canada.
The local ethics committees approved the study and written
informed consent from the donors was obtained in accordance
with the Declaration of Helsinki.
Clinical data of cases investigated by GEP are provided in Table
S1. The tumor cells in all cases were positive for CD20 and
negative for CD30, CD15 and Epstein-Barr virus (EBER). An
independent series of 10 lymph nodes each from patients with
NLPHL (Fan patterns A and C), THRLBCL-like NLPHL
(NLPHL pattern E), and THRLBCL were investigated by
immunohistochemistry for confirmation purposes.
Purification of Cells
Twohundredtwenty tumor cells from fresh frozen lymph nodes
of 10 cases of typical NLPHL (pattern A/B/F,. Methods S1), 9
cases of THRLBCL-like NLPHL (pattern E) and 11 cases of
THRLBCL were laser microdissected as previously described
[12]. For comparison to tumor cells, CD77
+ normal GC B cells
were purified from fresh tonsils of healthy donors using magnetic
activated cell sorting (MACS; Miltenyi Biotech, Bergisch Glad-
bach, Germany), as reported previously [13].
Gene Expression Analysis
Microdissected and MACS purified cells were lysed in NUGEN
Direct Lysis Buffer and total RNA was amplified with the WT-
Ovation-One-direct-Kit according to the manufacturers protocol
(NUGEN, Bemmel, The Netherlands). The samples were labeled
with the Encore Biotin Module (NUGEN) and hybridized onto
Human Gene 1.0 ST Arrays (Affymetrix, Santa Clara, USA).
Detailed information on sample purification and statistical analysis
can be found in Methods S1 section. Gene expression data are
available through the GEO database (GSE47044).
Immunohistochemistry
Results of gene expression profiling were confirmed by
immunohistochemistry as previously described [14]. In brief,
paraffin sections of an independent series of 10 lymph nodes each
from patients with NLPHL (patterns A and C), THRLBCL-like
NLPHL (NLPHL pattern E), and THRLBCL were assessed for
Figure 1. Immunoarchitectural patterns of NLPHL, THRLBCL-like NLPHL and THRLBCL, modified after Fan et al. [5]. a.–d. CD20-
immunostainings (100x) of NLPHL patterns A and C, THRLBCL-like NLPHL and THRLBCL. e.–h. Schematic forms of immunoarchitectural patterns. Stars:
tumor cells, dots: reactive B cells. a./e. Typical NLPHL Fan pattern A; b./f. NLPHL Fan pattern C; c./g. THRLBCL-like NLPHL (Fan pattern E); d./h.
THRLBCL.
doi:10.1371/journal.pone.0078812.g001
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PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e78812Figure 2. Unsupervised hierarchical clustering and principal component analysis of gene expression profiles of microdissected
tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL, as well as sorted tonsillar GC B cells. a. Unsupervised hierarchical clustering of
NLPHL and THRLBCL - Spectrum of One Disease?
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Six reactive lymph nodes were likewise stained for BAG6/BAT3,
HIGD1A and UBD/FAT10. All cases were additionally stained
for CD163, CD4, CD8 and MUM1, as well as the follicular
dendritic cell (FDC) marker CD21 and follicular T helper (TFH)
markers PD1, CXCL13 and ICOS as described previously
[15,16]. Antibodies and staining procedures are summarized in
Table S2.
Quantification of Tumor Microenvironment
Immunohistochemical CD4-, CD8- and CD163-stainings of
the cases investigated by gene expression profiling and of
additional independent cases were quantified using a light
microscope equipped with a camera system (Microdissection
Axiovert 200M microscope, PALM, Bernried, Germany). For
each slide, three representative counting frames (122,824 mm
2)
were chosen, and the number of positively stained cells was
point-counted using PALM software as described previously
[15]. In tumors with a nodular infiltrate counting frames were
placed in the nodules, in predominantly diffuse infiltrates,
counting frames were set in the diffuse areas. Cell counting and
assessment of histological parameters were carried out in each
case without knowledge of the diagnosis and clinical parameters.
The data were tested for the presence of a Gaussian distribution
(Shapiro-Wilk-test). Significance was calculated using either
unpaired two-tailed Students t-test or Mann-Whitney-test.
The percentage of PD1
+, CXCL13
+ and ICOS
+ TFH cells was
estimated to be ,5%, or 10–90% in steps of 10%. The pattern of
FDCs in CD21 staining was classified as large nodules, small
nodules or absent.
Results
Gene Expression Profiles of the Tumor Cells of NLPHL
and THRLBCL are Closely Related
To elucidate the relatedness of the tumor cells of NLPHL,
THRLBCL-like NLPHL and THRLBCL, we generated global
gene expression profiles of microdissected tumor cells from 10
cases of NLPHL, 9 cases of THRLBCL-like NLPHL, and 11 cases
of THRLBCL, as well as 5 samples of MACS-isolated tonsillar GC
B cells. We performed an unsupervised hierarchical clustering of
the gene expression profiles of all cases together with the GC B
cells (Fig. 2a). A core group of 7 of 10 typical NLPHL was
identified that clustered closely together. However, this group did
not cluster completely separately from the rest of the cases.
Instead, there was a continuous branching, and THRLBCL-like
NLPHL cases were intermingled with THRLBCL cases. The GC
B cells clustered in a separate group. Performing unsupervised
hierarchical clustering without GC B cells, a similar pattern with
continuous branching of the tumor cases was observed (Fig. S1). In
a principal component analysis (Fig. 2b), similar results were
obtained: the tumor cells of the single cases of each entity were
heterogeneously distributed and again the different entities did not
clearly separate.
Comparison of Tumor Cells of NLPHL and THRLBCL
Highlights Only Few Differentially Expressed Genes
In a supervised comparison of the global gene expression
patterns of the tumor cells from the NLPHL, THRLBCL-like
NLPHL and THRLBCL included in our analysis no differentially
expressed genes were identified if a false discovery rate (FDR)
below 0.1 was applied. After relaxing the FDR to 0.3, allowing a
rate of 30% false positive discoveries, some differentially expressed
genes were obtained. Nevertheless, no differentially expressed
the gene expression profiles of the tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL as well as CD77
+ GC B cells. All probesets with a standard
deviation $0.9 (479 probesets) were considered. GC B cell samples are indicted by a grey bar. b. Principal component analysis of the gene expression
profiles of the tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL. All probesets with a standard deviation $1.2 (79 probesets, 40.18% diversity)
were considered.
doi:10.1371/journal.pone.0078812.g002
Table 1. Top 5 upregulated genes in pairwise comparisons between tumor cells of NLPHL, THRLBCL-like NLPHL and THRLBCL.
Comparison Top-5 Genes Fold change FDR
NLPHL vs THRLBCL SEPT14 2.7 0.27 Septin 14
RGS13 2.3 0.21 Regulator of G-Protein Signalling 13
AMY2A 2.2 0.21 Amylase alpha 2A
SNORD75 2.2 0.29 Small nucleolar RNA 75
RPS27 2.2 0.21 Ribosomal protein S27
NLPHL vs THRLBCL-like NLPHL – – – –
THRLBCL vs NLPHL BAT3 3.5 0.27 HLA-B associated transript 3
MT2A 3.1 0.24 Metallothionein 2A
MT1H 3.1 0.21 Metallothionein 1H
CXCL9 2.3 0.22 Chemokine ligand 9
S100A8 2.1 0.22 S100 Calcium-binding protein A8
THRLBCL-like NLPHL vs NLPHL – – – –
THRLBCL vs THRLBCL-like NLPHL – – – –
THRLBCL-like NLPHL vs THRLBCL HIGD1A 2.4 0.10 HIG hypoxia inducible domain family member 1A
p-values ,0.05. FDR (false discovery rate),0.3. vs=versus.
doi:10.1371/journal.pone.0078812.t001
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THRLBCL-like NLPHL. Solely one differentially expressed gene
was found between THRLBCL-like NLPHL and THRLBCL
(HIGD1A, a hypoxia-inducible target gene [17], 2.4-fold upregu-
lated in THRLBCL-like NLPHL, FDR=0.104, p,0.0001;
Table 1). In the comparison of LP cells of typical NLPHL with
tumor cells of THRLBCL, the highest number of differentially
expressed genes was observed; 16 genes were upregulated more
than 1.7-fold in the LP cells of typical NLPHL, including
HIGD1A (upregulated 2.0-fold, Table 1, Table S3). Another
upregulated gene was SEPT14, a GTP-binding cytoskeletal
protein implicated in multiple cellular functions, including
apoptosis, cell polarity, cell cycle regulation, and oncogenesis
[18]. Further upregulated genes were a regulator of G protein
signaling (RGS13), amylase alpha 2A (AMY2A) and ribosomal
proteins (RPS27 and MRPL51). Among the 8 genes upregulated
in the tumor cells of THRLBCL compared to LP cells of typical
NLPHL (Table 1, Table S4), BAT3/BAG6 was most strongly
upregulated (3.5-fold). BAT3/BAG6 is a protein with multiple
functions, including acetylation of p53 [19], degradation of
mislocalized proteins [20] and regulation of apoptosis [21].
In the supervised comparisons with GC B cells (p,0.05, FDR
,0.1, Fold change .1.7), 44 genes were upregulated in the LP
cells of typical NLPHL (Table S5), 40 genes in the LP cells of
THRLBCL-like NLPHL (Table S6) and 28 genes in the tumor
cells of THRLBCL (Table S7). Of note, ubiquitin-like modifier
UBD/FAT10, which is modifying p53 [22], mediating NF-
kappaB activation [23], and can be induced by pro-inflammatory
stimuli [24], was particularly highly upregulated. CXCL13,
expressed in follicular T helper cell derived lymphomas [25],
was 1.7- and 1.9-fold upregulated in LP cells of typical NLPHL
and THRLBCL-like NLPHL, respectively, as well as 1.5-fold in
tumor cells of THRLBCL.
Identification of Novel Immunohistochemical Markers
Immunohistochemical stainings for the proteins HIGD1A,
BAT3/BAG6, UBD/FAT10 and CXCL13, identified by gene
expression profiling, were performed on independent cases of
typical NLPHL (patterns A and C), THRLBCL-like NLPHL
(pattern E) and THRLBCL. HIGD1A expression was detected
more frequently and stronger in tumor cells of different variants of
NLPHL (6/10, 8/10 and 9/10 cases, respectively in the patterns
A, C and E) than in THRLBCL (4/10 cases, Table 2, Fig. 3). In
contrast, a strong expression of BAT3/BAG6 was found in tumor
cells of THRLBCL (10/10 cases, Fig. 3), but a somewhat weaker
expression was also observed in different variant patterns of
NLPHL (10/10 and 8/10 cases for patterns A and C, respectively)
and THRLBCL-like NLPHL (7/10 cases). UBD/FAT10 was
rarely expressed in typical NLPHL (1/10 cases each for patterns A
and C), but was more frequently expressed in THRLBCL-like
NLPHL (5/10 cases) and THRLBCL (4/10). HIGD1A and
BAT3/BAG6 were also weakly expressed in a subset of GC B cells
in reactive lymph nodes, whereas UBD/FAT10 was negative.
CXCL13 was expressed in the tumor cells in a small subset of
cases of NLPHL variants with predominant extranodular locali-
zation of the tumor cells (4/10 and 2/10 cases, respectively, for
NLPHL pattern C and THRLBCL-like NLPHL) and in
THRLBCL (2/10 cases), consistent with the weak upregulation
observed in tumor cells compared to the GC B cells in the gene
expression profiling.
Quantification of the Microenvironment Reveals
Differences between Typical NLPHL and THRLBCL, and
Similarities between THRLBCL-like NLPHL and THRLBCL
Since gene expression profiling of tumor cells did not reveal
clear differences between NLPHL and THRLBCL, we aimed to
further characterize the microenvironment of the different entities
in order to evaluate the importance of the microenvironment. It is
well known that reactive T cells in THRLBCL mainly correspond
to CD8
+ T cells with only few CD4
+ T cells [26,27]. Therefore, we
determined the number of CD4
+ and CD8
+ T cells as well as
CD163
+ histiocytes in histological sections of NLPHL and
THRLBCL. CD4
+ T-cell counts in THRLBCL (median 3091/
mm
2) were significantly lower than in typical NLPHL (pattern A:
median 6433/mm
2, p=0.002, t-test; pattern C: 5966/mm
2,
p=0.011, t-test; Fig. 4a). The difference in CD4
+ T-cell amount
of THRLBCL-like NLPHL (median 4374/mm
2) compared to
typical NLPHL was not significant. Furthermore, CD8
+ T-cell
counts did not significantly differ between typical NLPHL,
THRLBCL-like NLPHL and THRLBCL (Fig. 4b). In addition,
the amount of CD163
+ histiocytes was determined. The average
number of CD163
+ histiocytes/mm
2 was significantly higher in
both THRLBCL-like NLPHL and THRLBCL (median 2957 and
2743/mm
2, respectively) compared to typical NLPHL (pattern A
and C median 85 and 689/mm
2,p ,0.001, Mann-Whitney-test,
Fig. 4c).
In ten cases each, the percentage of reactive T cells expressing
the TFH cell markers PD1, CXCL13 and ICOS was assessed.
Generally, typical NLPHL (patterns A and C) showed a higher
content of TFH cells compared to THRLBCL-like NLPHL and
THRLBCL (Fig. S2). PD1
+ T cells were slightly more frequent
(medians 30% in NLPHL pattern A, 35% in pattern C, 15% in
THRLBCL-like NLPHL and 5% in THRLBCL) compared to
CXCL13
+ T cells (medians 20% in NLPHL pattern A, 15% in
pattern C, 7.5% in THRLBCL-like NLPHL and 5% in
THRLBCL) and ICOS
+ T cells (medians 20% in NLPHL pattern
A, 25% in pattern C and 5% each in THRLBCL-like NLPHL and
THRLBCL).
In previous studies, CD57
+ and PD1
+ T cells rosetting around
tumor cells were frequently observed in typical NLPHL, but less
often in THRLBCL-like NLPHL [28,29]. We therefore studied
the cases investigated also for the presence of rosetting T cells
expressing PD1, ICOS, CXCL13 and MUM1 (Table 3). PD1
+
rosetting T cells were frequently observed in typical NLPHL
(pattern A: 8/10 cases and pattern C: 6/10 cases), whereas no
PD1
+ rosetting T cells were found in THRLBCL-like NLPHL and
THRLBCL. Likewise, MUM1
+ T cell rosettes were more
frequently observed in typical NLPHL (pattern A and C: 6/10
cases each) than in THRLBCL-like NLPHL and THRLBCL,
where they were present in 2/10 cases each. CXCL13
+ and
ICOS
+ rosetting T cells were only rarely observed in typical
Table 2. Immunohistochemical validation of genes expressed
in the tumor cells of NLPHL and THRLBCL in an independent
set of cases.
HIGD1A BAT3 FAT10 CXCL13 ICOS
Typical NLPHL
(Pattern A)
6/10 10/10 1/10 0/10 1/10
Typical NLPHL
(Pattern C)
8/10 8/10 1/10 4/10 0/10
THRLBCL-like
NLPHL (Pattern E)
9/10 7/10 5/10 2/10 5/10
THRLBCL 4/10 10/10 4/10 2/10 1/10
doi:10.1371/journal.pone.0078812.t002
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NLPHL and THRLCBL cases could be identified, with tumor
cells expressing ICOS (Table 2, Fig. 3). The majority of these cases
(5/7) belonged to the THRLBCL-like NLPHL group. However,
one ICOS
+ case each was also found in the NLPHL pattern A and
THRLBCL group. Interestingly, in all these cases the content of
reactive ICOS
+ T cells was very low (in all cases #10%). We also
evaluated the gene expression data for ICOS and ICOS-ligand
(ICOSLG) expression in the different lymphoma subsets, assuming
cases with log2 expression values $7.0 to show an expression of
Figure 3. Validation on protein level of genes expressed in both THRLBCL-like NLPHL and THRLBCL identified by gene expression
profiling. a., b. and c.: Strong expression of BAT3/BAG6 in the tumor cells of typical NLPHL (pattern A), THRLBCL-like NLPHL and THRLBCL, 200x.
Inset: Positive tumor cells in 400x. d., e. and f.: Expression of HIGD1A in the tumor cells of typical NLPHL (pattern A), THRLBCL-like NLPHL and
THRLBCL, 200x. Inset: Positive tumor cells in 400x. g., h. and i.: Expression of UBD/FAT10 in the tumor cells of typical NLPHL (pattern A), THRLBCL-like
NLPHL and THRLBCL, 200x. Inset: Positive tumor cells in 400x. j., k. and l.: Expression of CXCL13 in rosetting T cells of typical NLPHL (pattern A) and
in the tumor cells of THRLBCL-like NLPHL and THRLBCL, 200x. Insets in 400x. m., n. and o.: Expression of ICOS in the tumor cells of typical NLPHL
(pattern A), THRLBCL-like NLPHL and THRLBCL, 200x. Inset: Positive tumor cells in 400x.
doi:10.1371/journal.pone.0078812.g003
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cases only in rare cases (3 cases typical NLPHL, 1 case
THRLBCL-like NLPHL, 2 cases THRLBCL), whereas ICOSLG
was expressed in all cases as well as in the GC B cells.
The FDC content in the cases correlated very well with the
patterns studied: 9/10 NLPHL pattern A presented large FDC
nodules and one case presented small nodules. In 6/10 NLPHL
pattern C small FDC nodules dominated, whereas four cases
showed large nodules. In both the diffuse areas of THRLBCL-like
NLPHL as well as in the THRLBCL cases remnants of FDC were
not identified.
Discussion
In the present study we performed gene expression profiling of
microdissected LP cells of different variants of NLPHL (typical and
THRLBCL-like NLPHL) in comparison to tumor cells of
THRLBCL. Applying this method, we found an important
molecular overlap between the tumor cells of the different variants
of NLPHL and THRLBCL. We cannot exclude that this result is
influenced by technical limitations, like a strong amplification of
the RNA before array hybridization, causing loss of some
differentially expressed genes. However, applying the same
technique, we obtained numerous and up to 21-fold differentially
expressed genes in another study of microdissected cells [12]. Both
the unsupervised hierarchical clustering as well as the principal
component analysis revealed that there is often more heterogeneity
in global gene expression between two cases of one of the three
lymphoma entities analyzed than between cases of different
entities. Even in the pairwise supervised comparisons of NLPHL,
THRLBCL-like NLPHL and THRLBCL, very few consistently
differentially expressed genes were found. Thus, no indication was
found that the tumor cells of the three types of lymphomas show a
disease-specific gene expression pattern, which would have
supported a distinct pathogenesis and pathophysiology of the
tumor cells.
The lack of clear distinct gene expression patterns between
NLPHL and THRLBCL as seen in our analysis is in line with
results of other studies, in which it was not possible to discriminate
both entities on the basis of differential marker expression in the
tumor cells [11,13,30]. Indeed, a previously published gene
expression study comparing the gene expression profiles of tumor
cells of different B cell lymphomas reported that tumor cells of
THRLBCL were most closely related to tumor cells of typical
nodular NLPHL [13]. However, THRLBCL-like NLPHL was not
included in the analysis, nor in other studies, which aimed to
identify differentially expressed markers between the two entities
[30,31,32,33]. So far, many commonly expressed genes in tumor
cells of both entities were identified, such as BCL6, CD75, EMA,
J-chain and PU.1, as well as a typical kappa light chain restriction
[11,34,35,36,37]. The only investigations which clearly point to a
distinct pathogenesis of both diseases are two comparative
genomic hybridization studies, in which a higher number and
different genomic aberrations were identified in NLPHL than in
THRLBCL [38,39]. However, these distinct genetic patterns
apparently do not translate into many consistently differentially
expressed genes, as implied from the present work.
The genes we identified to be expressed in typical NLPHL,
THRLBCL-like NLPHL and THRLBCL, were ubiquitin-like
modifiers like UBD/FAT10 and BAT3/BAG6, both interacting
with the tumor suppressor p53 [19,22]. In a previous study, p53
expression was observed in 72% of the tumor cells of THRLBCL
[11]. This is surprising, since BCL6 has been shown to
downregulate p53 [40], and BCL6 is strongly expressed in the
Figure 4. Quantification of the microenvironment in typical
NLPHL (patterns A and C), THRLBCL-like NLPHL (pattern E) as
well as THRLBCL. a. Numbers of CD4
+ T cells/mm
2 in typical NLPHL
(pattern A: n=14 and pattern C: n=13), THRLBCL-like NLPHL (n=14)
and THRLBCL (n=25). (*p,0.05, **p,0.01, unpaired t-test). b. Numbers
of CD8
+ T cells/mm
2 in typical NLPHL (pattern A: n=14, pattern C:
n=15) and THRLBCL-like NLPHL (n=12) as well as THRLBCL (n=22). c.
Numbers of CD163
+ macrophages/mm
2 in NLPHL (pattern A and C as
well as THRLBCL-like NLPHL: n=14, each) and THRLBCL (n=25),
(***p,0.001, Mann-Whitney-test).
doi:10.1371/journal.pone.0078812.g004
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[11,41]. It has been shown that BAT3/BAG6 can be released
from tumor cells in response to stress signals [42]. Both BAT3/
BAG6 as well as UBD/FAT10 expression was shown to be
increased during inflammatory response [21,43]. This may be
caused by the release of proinflammatory factors from macro-
phages of THRLBCL [12]. Moreover, HIGD1A, an important
player in the maintenance of normal mitochondrial function in
hypoxia [17,44,45], was expressed in a subset of cases. Thus, the
genes expressed in tumor cells of both entities hint at a severe
stress, possibly related to a proinflammatory milieu created by
macrophages and epithelioid cells. Expression of CXCL13 was
only rarely observed in tumor cells of THRLBCL-like NLPHL as
well as THRLBCL, but never in typical NLPHL (pattern A).
Instead, 3 out of 10 NLPHL pattern A cases presented CXCL13-
positive rosetting T cells (Fig. 3). It might be speculated that
CXCL13-expression supports independency of the tumor cells
from FDC networks and CXCL13-positive rosetting T cells
[28,46], which are both absent in THRLBCL-like NLPHL and
THRLBCL. A similar observation was made for ICOS expression
in the tumor cells of one case each of typical NLPHL and
THRLBCL as well as in five cases of THRLBCL-like NLPHL. If
aberrant ICOS expression in the tumor cells occurred, only few
ICOS
+ TFH cells were found in the reactive microenvironment.
Therefore, an autocrine stimulation of the tumor cells via
ICOSLG could be a possible explanation, particularly since in
the gene expression analysis ICOSLG was expressed in the tumor
cells of all NLPHL and THRLBCL cases. Since the majority of
typical NLPHL usually include a relatively high proportion of
ICOS
+ TFH cells, LP cells would not benefit from aberrant ICOS
expression and therefore LP cells usually appear to be ICOS
2
[47].
In a previous whole tissue gene expression study, large
differences in the gene expression of the microenvironment of
typical NLPHL and THRLBCL were found [48]. In the present
study, we confirmed differences in the composition of the
microenvironment of typical NLPHL (pattern A and C) and
THRLBCL in terms of TFH cell and macrophage content.
Reduced numbers of TFH cells in diffuse variants of NLPHL have
previously been described [28,29]. However, we could not
demonstrate clear differences between THRLBCL-like NLPHL
and THRLBCL. Furthermore, MUM1
+ rosetting T cells were
present in rare cases of both THRLBCL-like NLPHL and
THRLBCL. As patients were described to present with NLPHL
and THRLBCL and vice versa in sequential biopsies [10], it seems
very unlikely that the tumor cells in THRLBCL should be
fundamentally different from NLPHL. Indolent Non-Hodgkin
lymphomas frequently progress into aggressive B cell lymphomas,
but very rarely primary aggressive B cell lymphomas relapse as an
indolent B cell lymphoma, without a previous history of indolent
Non-Hodgkin lymphoma. Therefore, we speculate that
THRLBCL-like NLPHL and THRLBCL represent the same
disease and may be an aggressive variant of NLPHL with unique
changes in the microenvironment.
In recent studies, the composition of the microenvironment and
particularly a high content of tissue macrophages was identified to
be an adverse prognostic factor in classical Hodgkin lymphoma
(cHL) [49,50,51,52]. Furthermore, not only the composition of the
microenvironment in the tissue, but additionally a low ratio of
absolute lymphocyte/monocyte count in the peripheral blood was
identified as an independent prognostic factor for overall and
progression free survival in patients with cHL and NLPHL
[53,54,55]. We recently demonstrated a link between low CD4
+
blood counts and a low amount of CD4
+ T cells in combination
with a high content of macrophages in the tissues affected by cHL
in HIV patients [15]. Although the amounts of CD4
+ T cells in
THRLBCL and THRLBCL-like NLPHL were not comparable to
the setting of HIV-associated cHL, they were significantly
decreased in THRLBCL compared to typical NLPHL. The
macrophage counts in THRLBCL and THRLBCL-like NLPHL
were in the range of HIV-associated cHL [15]. One possible
hypothesis to explain this observation could be that monocytes/
macrophages are attracted by the tumor cells to the affected lymph
nodes via CCL5 [56,57] in the absence or relative lack of CD4
+ T
cells in the blood. In the present study, CCL5 was upregulated in
all tumor samples compared to GC B cells, but the upregulation
was significant only in THRLBCL tumor cells (1.5-fold upregula-
tion, FDR=0.037, p=0.014, t-test). We therefore propose that
the manifestation of typical NLPHL or THRLBCL-like NLPHL/
THRLBCL may depend on the ratio of CD4
+ T cells/monocytes
in the blood of the patient at diagnosis. Similar to HIV-patients
with cHL [58], THRLBCL-like NLPHL and THRLBCL patients
generally present with advanced disease stages [7]. In the present
study, we cannot finally clarify the relationship between NLPHL
and THRLBCL. However, since the clinical presentation of the
patients with both diseases is distinct, requiring different treatment
approaches, it appears practical to furtherhin separate patients in
the two diagnostic categories of NLPHL and THRLBCL. Our
observation of a highly similar immunophenotype of the tumor
cells in both entities together with a remarkably different
composition of the microenvironment suggest a fundamental role
of the patients immune status at diagnosis. Further studies,
particularly investigating common and distinct genomic aberra-
tions and the immune status at diagnosis, will be necessary to
corroborate this hypothesis.
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*Cases were scored positive if positive rosetting T cells were observed around at least 5% of the tumor cells.
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